Key insights from lung cancer research at ASCO 2025

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC

New MOAs in prostate cancer treatment - what’s next?

Social determinants and survival outcomes in early-onset colorectal cancer in the US

Low frequency of dihydropyrimidine dehydrogenase variants in Mexican GI cancers should induce testing guideline reform

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy

ASCO 2025: Update on blood-based cancer assays

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing

ASCO 2025: Latest in EGFR positive NSCLC

Pro-inflammatory diets associated with worse outcomes for stage III colon cancer

Exercise programme may lower risk of recurrence and death for some colon cancer survivors